Clinical trials: Oxycodone
Recreational Drug Use
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)
The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.
- Trial name
- NCT05567354
- Testing
- PF614, Oxycodone
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Healthy
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of PF-00345439 formulations taken whole under fed conditions and after chewing under fasted conditions in healthy…
- Trial name
- NCT01717027
- Testing
- Oxycodone
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Analgesia, Acute Pain
A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers
This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 5-dosing period study to characterize the pharmacokinetics (process by which oxycodone is absorbed…
- Conditions
- Analgesia, Acute Pain, Chronic Pain, Narcotic Abuse
- Trial name
- NCT01530542
- Testing
- oxycodone hydrochloride, marketed oxycodone hydrochloride
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.
Opioids are potent painkillers but come with serious adverse effects ranging from addiction to potentially lethal respiratory depression via activation of μ-opioid receptors (MOP) at specific sites in the central nervous system.
- Trial name
- NCT05491785
- Testing
- Cebranopadol 600 µg, Cebranopadol 800 µg, Cebranopadol 1000 µg
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Healthy Volunteers
Single-Dose PK Study of an Oxycodone/Acetaminophen Solution in Healthy Subjects
A single-dose study evaluating the oral PK of an oxycodone/apap solution in healthy subjects under fasted conditions
- Trial name
- NCT02966860
- Testing
- Oral solution OC/APAP
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Healthy
Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users
The purpose of the present study is to assess prospectively the abuse potential of gabapentin when taken with and without oxycodone compared to placebo in healthy non-drug-dependent recreational opioid drug users under fasted…
- Trial name
- NCT07813026
- Testing
- Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Viatris Inc.
Healthy
Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)
The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).
- Trial name
- NCT00955110
- Testing
- Oxymorphone ER, Oxycodone CR, Hydromorphone
- Where
- Canada
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Healthy Volunteers
Evaluation of Oral PF614 Relative to OxyContin (PF614-102)
This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B).
- Trial name
- NCT05043766
- Testing
- PF614, Naltrexone Hydrochloride, OxyContin
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Healthy
To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80 mg) relative to the original OxyContin® (OXY) formulation (80 mg) in the fed state.
- Trial name
- NCT01101178
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Healthy
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (10 mg) manufactured at the Totowa, NJ facility relative to the formulation (10 mg) manufactured at the Wilson, NC facility in the fasted…
- Trial name
- NCT01101308
- Testing
- Reformulated OXY (Totowa) (oxycodone HCl), Reformulated OXY (Wilson) (oxycodone HCl)
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Healthy
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug.
- Trial name
- NCT01677065
- Testing
- Oxycodone controlled-release test formulation, Immediate-release reference drug
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80 mg) relative to the original OxyContin® (OXY) formulation (80 mg) in the fasted state.
- Trial name
- NCT01101191
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Healthy
Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets
The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available…
- Trial name
- NCT00853736
- Testing
- Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Healthy
Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets
The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 15 mg to an equivalent oral dose of a commercially available…
- Trial name
- NCT00853320
- Testing
- Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Healthy
Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone
The purpose of this study is to estimate the effects of food and of sprinkling ALO-02 pellets on applesauce on the bioavailability of oxycodone and naltrexone/6- beta-naltrexol from an extended release pellets-in-capsule…
- Trial name
- NCT01456507
- Testing
- ALO-02 (Oxycodone Naltrexone)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Substance Abuse
A Comparison of How Likely it is That Different Tablets of Oxycodone Will be Broken up and Snorted by Adults Who Sometimes Take Drugs for Pleasure
The trial comprises an Enrollment Visit, a Qualification Phase, a Treatment Phase (including 3 treatment periods), a Final Examination, and a Follow-up Phone Call.
- Trial name
- NCT03765346
- Testing
- Oxycodone IR ADF, Oxycodone API powder
- Where
- Canada
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Healthy
Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation
The study is designed to test whether or not the rate and extent of absorption of oxycodone from a proprietary controlled-release formulation is significantly affected by co-administration of alcohol compared with controlled…
- Trial name
- NCT01677039
- Testing
- Test formulation administered with water, Test formulation administered with 20% ethanol, Test formulation administered with 40% ethanol
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
To assess the bioequivalence of reformulated OXY tablets (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fed state.
- Trial name
- NCT01100320
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Pharmacokinetics
Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)
A single dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is solution is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release (ER) capsule prototypes.
- Trial name
- MPAR-101 (NCT05090280)
- Testing
- PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Healthy
A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting Conditions
To compare the relative bioavailability of oxycodone HCl 5 mg / ibuprofen 400 mg tablets (Actavis Elizabeth LLC, Lot No. PI-1565) with that of COMBONOX® tablets (Forest Pharmaceuticals, Inc., Lot No.
- Trial name
- NCT00864357
- Testing
- Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose, COMBONOX® tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.